Intra-Cellular Sues to Stop 7 Copies of Its Only Drug, Caplyta
Intra-Cellular Therapies Inc. filed lawsuits seeking to block copies of Caplyta proposed by Sandoz Group and six other generic-drug makers, alleging infringement of as many as 16 patents for the bipolar depression and schizophrenia treatment.